期刊文献+

缓释药物微粒超临界流体制备技术研究进展 被引量:1

Research Development of Supercritical Fluid Technology for Release Drug Nanoparticle
在线阅读 下载PDF
导出
摘要 复合药物微粒作为新型的药物载体,因具有较好的超细小的粒径、生物相容性及良好的体内分布而受到广泛的关注。复合药物微粒可包载蛋白质、多肽、基因等大分子药物,还可实现缓释、控释、靶向给药等,使药物在病灶处释药,具有减少给药剂量、延长作用时间及降低机体损伤等优点。文章简要介绍利用超临界流体膨胀技术、流化床技术、超临界流体辅助渗透技术、超临界流体反溶剂技术制备药物缓释复合微粒的研究现状及应用前景。 The composite drug micro-particle as new drug carrier attracts much attention because of its super small particle size, biologic consistent character and perfect bio-distribution. Multi-compound drug micro-particle can not only load macromolecular drug such as protein, peptide and gene, but also make slow -release, controlled -release and targeting drug come true. These cause drug to release in the lesions with some advantages, such as reducing dosage, prolonging reaction time and decreasing body injuries. This paper gives a brief description of the present situation and the potential applications of the preparation of multi -compound drug micro -particle by using the supercritical fluid solutions, the fluidized-bed coating, the technology of supercritical fluid accessorial infiltration and the supercritical antisolvent process.
出处 《纳米科技》 2010年第5期55-60,共6页
关键词 超临界流体 复合药物微粒 药物微胶囊 脂质体 supercritical fluid multi-compound drug micro-particle drug microcapsule liposome
  • 相关文献

参考文献2

二级参考文献23

  • 1单宝锋,张继宇,方昆凡.振动流化床喷雾造粒中颗粒成长机理的研究[J].沈阳航空工业学院学报,1995,12(4):27-32. 被引量:2
  • 2Rubino OP. Fluid-bed technology overview and criteria for process selection[J]. Pharm Tech, 1999,23(6): 104-113.
  • 3Watano S, Suzuki T, Taira T, et al. Continuous monitoring and mechanism of electrostatic charge of powder in fluidized bed process[J]. Chem Pharm Bull, 1998, 46(9):1438-1441.
  • 4Ichikawa H, Fukumori Y. Microagglomeration of pulverized pharmaceutical powders using the Wurster process Ⅰ.Preparation of highly drug-incorporated, subsieve-sized core particles for subsequent microencapsulation by film-ciating [J]. Int J Pharm, 1999, 180(2):195-210.
  • 5Sugao H, Yamazaki S, Shionzawa H, et al. Taste masking of bitter drug powder without less of bioavailability by heat treatment of wax-coated microparticles[J]. J Pharm Sci,1998, 87(1):96-100.
  • 6Knezevic Z, Gosak D, Hraster M, et al. Fluid-bed microencapsulation of ascorbic acid [J].J Microencapsul,1998, 15(2):237-252.
  • 7Fukmori Y, Ichikawa H, Yamaoka Y, et al. Effect of additives on physical properties of fine ethyl celMose microcapsules prepared by the Wurster process[J]. Chem pharm Bull, 1991, 39(1):164-169.
  • 8Siepmann J, Paeratakul O, Bodmeier R. Modeling plasticizer uptake in aqueous polymer dispersion[J]. Int J Pharm, 1998, 165(2):191-200.
  • 9Nakano T, Yuasa H, Kanaya Y. Suppression of agglomeration in fluidized bed coating. Ⅲ. Hofmeister series in suppression of particle agglomeration[J]. pharm Res, 1999,16(10):1616-1620.
  • 10Nakano T, Yuasa H. Suppression of agglomeration in fluidizad bed coating. Ⅳ. Effects of sodium citrate concentration on the suppression of particle agglomeration and the physical properties of HPMC film[J]. Int J Pharm, 2001,215(1/2):3-12.

共引文献23

同被引文献12

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部